Voleon Capital Management’s Biogen BIIB Stock Holding History

Voleon Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,253	Closed	-$316K	–	808
2025 Q3	$316K	Buy	+2,253	New	+$305K	0.01%	707
2019 Q3	–	Sell	-72,000	Closed	-$16.8M	–	155
2019 Q2	$16.8M	Buy	+72,000	New	+$16.6M	0.96%	27
2019 Q1	–	Sell	-77,000	Closed	-$23.2M	–	26
2018 Q4	$23.2M	Buy	+77,000	New	+$24.6M	2.21%	16

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Voleon Capital Management's BIIB Position: Q4 2025 in Review

Voleon Capital Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 2,253 shares — an estimated $316K sold.

Voleon Capital Management first reported a position in BIIB in Q4 2018 and held it in 3 quarters. The position peaked at $23.2M in Q4 2018. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Voleon Capital Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Voleon Capital Management sold 2,253 Biogen shares in Q4 2025, an estimated $316K.
Voleon Capital Management first reported a position in Biogen in Q4 2018 and held it in 3 quarters.
Voleon Capital Management's Biogen position peaked at $23.2M in Q4 2018.
1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Voleon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.